Imfinzi approved in EU for biliary tract cancer
21 December 2022 07:00 GMT Imfinzi plus chemotherapy approved in the EU as first immunotherapyregimen for patients with advanced biliary tract cancer Approval based on TOPAZ-1 updated survival results showing Imfinzicombination reduced risk of death by 24% vs. chemotherapy alone AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval by the European Commission was based on